United Therapeutics, Liquidia settle Yutrepia patent litigation, agree to dismiss cases with prejudice

By Public Technologies
  • United Therapeutics reached a settlement with Liquidia to end multiple patent disputes tied to Yutrepia sales and labeling.
  • Liquidia must pay USD 185 million within 30 business days for past PH-ILD sales from June 2, 2025 through execution.
  • Liquidia also agreed to pay USD 145.4 million in two installments due by Jan. 31, 2027 and Apr. 30, 2027.
  • United Therapeutics will pay Liquidia USD 10 million to resolve a separate New Jersey case involving Sandoz and RareGen.
  • Claims against former Liquidia executive Robert Roscigno, as an individual, remain pending and were excluded from the releases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-115723), on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.